Epidemiology of gastro-oesophageal reflux disease: a systematic review, Gut, vol.54, issue.5, pp.710-717, 2005. ,
DOI : 10.1136/gut.2004.051821
Meta-Analysis: Obesity and the Risk for Gastroesophageal Reflux Disease and Its Complications, Annals of Internal Medicine, vol.143, issue.3, pp.199-211, 2005. ,
DOI : 10.7326/0003-4819-143-3-200508020-00006
Obesity: A Challenge to Esophagogastric Junction Integrity, Gastroenterology, vol.130, issue.3, pp.639-649, 2006. ,
DOI : 10.1053/j.gastro.2005.12.016
Body Mass Index and the Efficacy of Acid-Mediating Agents for GERD, Digestive Diseases and Sciences, vol.28, issue.9, pp.2313-2317, 2008. ,
DOI : 10.1007/s10620-008-0414-8
Pharmacokinetic considerations in the obese, Best Practice & Research Clinical Anaesthesiology, vol.25, issue.1, pp.27-36, 2011. ,
DOI : 10.1016/j.bpa.2010.12.002
Effect of Obesity on the Pharmacokinetics of Drugs in Humans, Clinical Pharmacokinetics, vol.16, issue.5 Pt 1, pp.71-87, 2010. ,
DOI : 10.2165/11318100-000000000-00000
Effects of Obesity on Pharmacokinetics, Clinical Pharmacokinetics, vol.26, issue.3, pp.215-231, 2000. ,
DOI : 10.2165/00003088-200039030-00004
Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4???-hydroxylation status, Clinical Pharmacology & Therapeutics, vol.52, issue.2, pp.143-154, 1995. ,
DOI : 10.1016/0009-9236(95)90192-2
The Impact of Body Mass Index on the Application of On-Demand Therapy for Los Angeles Grades A and B Reflux Esophagitis, The American Journal of Gastroenterology, vol.102, issue.4, pp.2387-2394, 2007. ,
DOI : 10.1080/003655298750026697
Body Mass Index Can Determine the Healing of Reflux Esophagitis With Los Angeles Grades C and D by Esomeprazole, The American Journal of Gastroenterology, vol.4, issue.Suppl 1, pp.1-6, 2008. ,
DOI : 10.1111/j.1572-0241.2008.01979.x
Double-Dosed Pantoprazole Accelerates the Sustained Symptomatic Response in Overweight and Obese Patients With Reflux Esophagitis in Los Angeles Grades A and B, The American Journal of Gastroenterology, vol.39, issue.5, pp.1046-1052, 2010. ,
DOI : 10.1080/003655298750026697
Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole, European Journal of Gastroenterology & Hepatology, vol.23, issue.10, pp.845-851, 2011. ,
DOI : 10.1097/MEG.0b013e32834991b7
Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs?, Best Practice & Research Clinical Gastroenterology, vol.24, issue.6, pp.905-921, 2010. ,
DOI : 10.1016/j.bpg.2010.09.004
PPI in gastroesophageal reflux disease, Balance of Usage PPI in GI Disease, pp.34-46 ,
Alternative Therapeutic Approaches to Chronic Proton Pump Inhibitor Treatment, Clinical Gastroenterology and Hepatology, vol.10, issue.4, pp.338-345, 2012. ,
DOI : 10.1016/j.cgh.2011.12.020
On-demand proton pump inhibitory treatment in overweight/obese patients with gastro-oesophageal reflux disease: are there pharmacodynamic arguments for using higher dose? Digestion, pp.56-63, 2013. ,
Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects, Alimentary Pharmacology and Therapeutics, vol.52, issue.1, pp.899-907, 2004. ,
DOI : 10.1111/j.1572-0241.2002.05769.x
pH probe positioning for 24-hour pH-metry by manometry or pH step-up, European Journal of Gastroenterology & Hepatology, vol.16, issue.4, pp.375-382, 2004. ,
DOI : 10.1097/00042737-200404000-00002
Accurate positioning of the 24-hour pH monitoring catheter: Agreement between manometry and pH step-up method in two patient positions, World Journal of Gastroenterology, vol.13, issue.46, pp.6197-6202, 2007. ,
DOI : 10.3748/wjg.13.6197
Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors, The American Journal of Gastroenterology, vol.89, issue.108, pp.763-767, 1998. ,
DOI : 10.1046/j.1365-2036.1996.33175000.x
A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects, Alimentary Pharmacology and Therapeutics, vol.109, issue.11, pp.1079-1089, 1998. ,
DOI : 10.1074/jbc.272.36.22438
Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude, World J Gastroenterol, vol.9, pp.2583-2586, 2003. ,
Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors, Alimentary Pharmacology and Therapeutics, vol.122, issue.12, pp.1507-1514, 2003. ,
DOI : 10.1046/j.1365-2036.2002.0160s1031.x
Effects of single doses of rabeprazole 20??mg and esomeprazole 40??mg on 24-h intragastric pH in healthy subjects, European Journal of Clinical Pharmacology, vol.20, issue.Suppl 6, pp.685-689, 2006. ,
DOI : 10.1007/s00228-006-0148-5
Initial potency of lansoprazole and omeprazole tablets on pentagastrin-stimulated gastric acid secretion-a placebo-controlled study in healthy volunteers, Alimentary Pharmacology and Therapeutics, vol.25, issue.9, pp.1225-1229, 2000. ,
DOI : 10.1046/j.1365-2036.1997.157332000.x
Clinical Pharmacology of Proton Pump Inhibitors, Drugs, vol.14, issue.24, pp.2739-2754, 2003. ,
DOI : 10.2165/00003495-200363240-00004
Effects of obesity on the cytochrome P450 enzyme system, Int J Clin Pharmacol Ther, vol.37, pp.8-19, 1999. ,
Review article: relationship between the metabolism and efficacy of proton pump inhibitors - focus on rabeprazole, Alimentary Pharmacology and Therapeutics, vol.13, issue.s6, pp.11-19, 2004. ,
DOI : 10.1046/j.1365-2036.1999.00022.x